Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.34 |
| ▸ | CCR5 | P51681 | 9/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709698 | 0.83 | DPP7 (0.35) | CHRM1GHSR | |
| SCHEMBL10122242 | 0.77 | AGTR2 (0.33) | L3MBTL1AGTR2CCR5CHRM1GHSR | |
| SCHEMBL10121648 | 0.76 | GHSR (0.43) | L3MBTL1CCR5GHSR | |
| SCHEMBL1709678 | 0.75 | GHSR (0.43) | L3MBTL1AGTR2CCR5GHSR | |
| SCHEMBL1709666 | 0.74 | GHSR (0.43) | L3MBTL1AGTR2CCR5GHSR | |
| SCHEMBL10122264 | 0.73 | GHSR (0.44) | CCR5GHSR | |
| SCHEMBL10122295 | 0.73 | GHSR (0.50) | HTR2AGHSRUSP2HPGDHSD17B10 | |
| SCHEMBL10122225 | 0.72 | GHSR (0.44) | L3MBTL1CCR5CHRM1GHSROPRM1 | |
| SCHEMBL1709732 | 0.72 | GHSR (0.43) | AGTR2CCR5GHSR | |
| SCHEMBL10122251 | 0.72 | GHSR (0.34) | AGTR2CCR5CHRM1GHSROPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | GHSR, GHRHR, STS | L3MBTL1 4633/4885AGTR2 612/4885CCR5 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.